Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus olaparib in recurrent ovarian cancer (Ib/II)
CTR20210713Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Apr 2021
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Akeso, Inc.. Started Apr 2021; status: terminated.
02
Drugs
ivonescimabolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20210713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210713.